Gut Microbiota and Parkinson's Disease

NCT03710668 | Unknown

• 1 other identifier: GMAPD
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Over the past decade, experimental data has suggested a complex and bidirectional interaction between the gastrointestinal (GI) tract and the central nervous system (CNS), the so-called "Gut- Brain axis." . Changes in the gut microbiota composition may cause alterations in the gut barrier function and intestinal permeability, affecting not only GI epithelial cells and immune system, but also the ENS including both neurons and glial cells . The bidirectional brain-gut-microbiota axis interactions modulate pro- and anti-inflammatory responses. It has been suggested that the gut microbiota changes associated with intestinal inflammation may contribute to the initiation of α-syn misfolding. There is a growing number of evidence confirming that the gut microbiota alterations precede or occur during the course of PD. Importantly, some genetic risk factors may play a crucial role in the interactions between the brain-gut-microbiota axis with respect to gut inflammation. It has been also shown that the methylation status in the SNCA promoter region may affect α-syn expression and the risk for PD. Therefore, a potential role of the gut microbiota as an epigenetic factor influencing DNA methylation may be speculated. Moreover, genetic variant of the component of innate immune system - TREM2 (Triggering Receptor Expressed on Myeloid cells) has been reported to be associated with a higher risk for PD. The ε4 allele of apolipoprotein E (ApoE) has been shown to increase the risk for dementia in synucleinopathies such as PD. Potentially, ApoE genotype, by influencing bile acid secretion, could affect the composition of the gut microbiota to favor the development of organisms triggering misfolding. Moreover, three single nucleotide polymorphisms in CARD15 gene, known to be associated with Crohn's disease, have been also shown to be over-expressed in PD patients, supporting the observation that GI inflammation contributes to the pathogenesis of PD.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Effect of gut microbiota on pathogenesis of Parkinson's diseases

  the QIAamp DNA Stool mini kit to extract total bactria DNA Some genetic risk factors may play a crucial role in the interactions between the brain-gut-microbiota axis with respect to gut inflammation. It has been also shown that the methylation status in the SNCA promoter region may affect α-syn expression and the risk for PD

  1 year

Interventions

MRI if indicated RADIATION

MRI brain if indicated

Eligibility Criteria

• Age: 50 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Unified Parkinson's Disease Rating Scale (UPDRS) and the modified Hoehn \& Yahr Scale (H\&Y). Non-Motor Symptoms Scale (NMSS). Demographic and clinical data (Age, sex, age of onset, severity of disease, clinical symptoms and signs, Types of treatment, duration of treatment, number of attacks)

You may qualify if:

• (50) patients diagnosed with Parkinson's Disease .
• (50) Control group free from Disease .

You may not qualify if:

• prior surgeries.
• any patients or controls currently taking antibiotics or probiotic supplements.
• having a known history of disease with an disease such, autoimmune disorders , cardiac patients
• history of stroke ,rheumatoid arthritis, type-1-diabetes, and IBD .

Sponsors & Collaborators

• Alaa E Ahmed: lead

Biospecimen

Retention: SAMPLES WITH DNA

Stool Sample

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: October 8, 2018
• First Posted: October 18, 2018
• Study Start: January 1, 2019
• Primary Completion: January 1, 2020
• Study Completion: December 31, 2021
• Last Updated: October 18, 2018

Record last verified: 2018-10